Profile data is unavailable for this security.
About the company
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
- Revenue in USD (TTM)44.38m
- Net income in USD-16.78m
- Incorporated2015
- Employees113.00
- LocationProphase Labs Inc711 STEWART AVE, SUITE 200, GARDEN CITYNEW YORK 11530United StatesUSA
- Phone+1 (215) 345-0919
- Websitehttps://www.prophaselabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prenetics Global Ltd | 21.74m | -54.35m | 63.83m | 800.00 | -- | 0.3093 | -- | 2.94 | -4.60 | -5.31 | 1.94 | 16.91 | 0.0768 | 3.37 | 0.9505 | -- | -19.92 | -- | -24.55 | -- | 40.61 | -- | -259.40 | -- | 2.29 | -5.92 | 0.0112 | -- | 65.17 | -- | 75.91 | -- | -- | -- |
| CRYO-CELL International, Inc. | 31.37m | -9.73m | 72.37m | 82.00 | -- | -- | -- | 2.31 | -1.18 | -1.18 | 3.77 | -1.25 | 0.4908 | 10.31 | 4.74 | 382,579.60 | -15.23 | 0.4686 | -21.73 | 0.7099 | 72.79 | 70.09 | -31.02 | 0.8133 | 0.449 | 5.93 | -- | -- | 3.32 | 1.41 | -443.57 | -- | 60.30 | -- |
| Oncology Institute Inc | 324.24m | -67.88m | 79.52m | 800.00 | -- | 1.39 | -- | 0.2452 | -0.9187 | -0.9187 | 4.39 | 0.7691 | 1.38 | 23.08 | 7.89 | 405,298.80 | -35.28 | -- | -40.88 | -- | 18.37 | 19.54 | -25.62 | -9.99 | 3.73 | -8.16 | 0.6036 | -- | 28.42 | 23.43 | -99,919.12 | -- | 45.68 | -- |
| Cardiff Lexington Corp | 12.35m | -2.15m | 81.77m | 2.00 | -- | -- | -- | 6.62 | -0.0102 | -0.0109 | 0.0007 | 0.0058 | 0.7163 | -- | 1.32 | 6,173,760.00 | -8.97 | -52.27 | -23.24 | -- | 70.08 | 57.44 | -12.53 | -58.31 | -- | 1.13 | 0.4002 | -- | 21.45 | 49.15 | -1,701.81 | -- | -- | -- |
| Burning Rock Biotech Ltd (ADR) | 74.23m | -90.29m | 82.86m | 1.14k | -- | 0.7807 | -- | 1.12 | -0.8818 | -0.8818 | 0.7249 | 1.03 | 0.4091 | 1.75 | 3.57 | -- | -49.76 | -37.09 | -66.95 | -45.29 | 67.59 | 70.02 | -121.63 | -123.88 | 3.09 | -- | -- | -- | -4.58 | 20.81 | 32.69 | -- | -- | -- |
| ProPhase Labs Inc | 44.38m | -16.78m | 97.81m | 113.00 | -- | 1.98 | -- | 2.20 | -0.9544 | -0.9544 | 2.53 | 2.74 | 0.4943 | 7.20 | 1.21 | 392,778.80 | -18.69 | 0.9106 | -23.53 | 1.12 | 36.59 | 50.32 | -37.81 | 0.9325 | 2.10 | -18.06 | 0.1521 | 665.78 | -63.81 | 27.59 | -190.90 | -- | 86.46 | -- |
| American Oncology Network Inc | 1.28bn | -9.12m | 135.23m | 1.53k | -- | -- | -- | 0.1057 | -1.19 | -1.19 | 145.02 | -10.16 | -- | -- | -- | 838,809.80 | -- | -- | -- | -- | 6.47 | -- | -4.92 | -- | 1.38 | -3.52 | 0.5499 | -- | 11.27 | -- | -- | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 605.29k | 3.35% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 245.71k | 1.36% |
| HighTower Advisors LLCas of 31 Dec 2023 | 173.12k | 0.96% |
| Geode Capital Management LLCas of 31 Dec 2023 | 137.41k | 0.76% |
| Perritt Capital Management, Inc.as of 31 Dec 2023 | 85.90k | 0.48% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 58.51k | 0.32% |
| SVB Wealth LLCas of 31 Dec 2023 | 47.67k | 0.26% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 40.16k | 0.22% |
| Chapin Davis, Inc. (Investment Management)as of 31 Mar 2024 | 40.00k | 0.22% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 37.50k | 0.21% |
